| REVIEW ARTICLE |
|
| Year : 2000 | Volume
: 32
| Issue : 5 | Page : 256-268 |
Cancer chemotherapy and radiation induced emesis (CRIE): current and future therapeutic approaches
A Abraham, N Sridhar, A Veeranjaneyulu
Correspondence Address:
A Abraham
 Source of Support: None, Conflict of Interest: None  | Check |
Nausea and vomiting caused by radiation and chemotherapy in cancer patients often tends to be more traumatic than the disease itself. Classical anti-emetic agents have offered very little protection against cancer chemotherapy and radiation induced emesis (CRIE). Newer agents that have immense potential and efficacy to treat this type of emesis are the 5-HT3 antagonists and NK1 antagonists. The high cost of 5-HT3 antagonists calls for the use of prudent combination regimens so as to have cost-effective management of emesis in cancer patients. Delayed emesis, a problem often witnessed in CRIE cannot be managed by the administration of serotonergic antagonists alone. Hence a cost-effective combination regimen which includes classical anti-emetic drugs may perhaps find an important place in future therapeutic approaches. This review highlights the various aspects associated with CRIE, including its physiology and newer therapeutic agents available to treat CRIE.
[PDF]*
|
